{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topical+Corticosteroid+%28TCS%29", "query": { "intervention": "Topical Corticosteroid (TCS)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topical+Corticosteroid+%28TCS%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T11:03:15.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03131648", "title": "Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 802, "start_date": "2017-05-30", "completion_date": "2019-10-10", "has_results": true, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03131648" }, { "nct_id": "NCT06311682", "title": "A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab + TCS", "type": "DRUG" }, { "name": "Placebo + TCS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Months to 11 Years" }, "enrollment_count": 195, "start_date": "2024-06-10", "completion_date": "2028-04-28", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 15, "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • Palo Alto, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06311682" }, { "nct_id": "NCT05724199", "title": "A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Rocatinlimab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 746, "start_date": "2023-02-21", "completion_date": "2024-12-04", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05724199" }, { "nct_id": "NCT03100344", "title": "Dose-ranging Study of Nemolizumab in Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2017-06-14", "completion_date": "2018-09-21", "has_results": true, "last_update_posted_date": "2019-10-22", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03100344" }, { "nct_id": "NCT05559359", "title": "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis", "Eczema" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Topical Corticosteroid (TCS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 377, "start_date": "2022-10-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05559359" }, { "nct_id": "NCT03809663", "title": "A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tezepelumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 251, "start_date": "2019-03-15", "completion_date": "2020-12-22", "has_results": true, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 16, "location_summary": "Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Alpharetta", "state": "Georgia" }, { "city": "Springfield", "state": "Illinois" }, { "city": "West Dundee", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03809663" }, { "nct_id": "NCT06627335", "title": "An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pregnancy Related", "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib Cream", "type": "DRUG" }, { "name": "TCS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "FEMALE", "summary": "14 Years and older · Female only" }, "enrollment_count": 5621, "start_date": "2023-03-27", "completion_date": "2028-08-15", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 1, "location_summary": "Morrisville, North Carolina", "locations": [ { "city": "Morrisville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06627335" }, { "nct_id": "NCT04183335", "title": "Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurodermatitis" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moisturizers", "type": "DRUG" }, { "name": "Low to medium potent topical corticosteroids", "type": "DRUG" }, { "name": "Topical calcineurin inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 151, "start_date": "2019-12-12", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 21, "location_summary": "Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04183335" }, { "nct_id": "NCT05387707", "title": "Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pruritus", "Atopic Dermatitis" ], "interventions": [ { "name": "difelikefalin 0.25 mg", "type": "DRUG" }, { "name": "difelikefalin 0.5 mg", "type": "DRUG" }, { "name": "TCS Cream", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cara Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 287, "start_date": "2022-08-16", "completion_date": "2024-02-02", "has_results": false, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 61, "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05387707" }, { "nct_id": "NCT00121381", "title": "Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Pimecrolimus plus topical corticosteroid (TCS)", "type": "DRUG" }, { "name": "Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 400, "start_date": "2005-05", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2008-01-15", "last_synced_at": "2026-09-24T11:03:15.277Z", "location_count": 13, "location_summary": "Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00121381" } ] }